Recombinant Mouse CD40/TNFRSF5 Fc Chimera Protein, CF
R&D Systems, part of Bio-Techne | Catalog # 1215-CD
Key Product Details
Source
Accession #
Structure / Form
Conjugate
Applications
Product Specifications
Source
Mouse CD40 (Val24-Arg193) Accession # P27512 |
DIEGRMD | Human IgG1 (Pro100-Lys330) |
6-His tag |
N-terminus | C-terminus |
Purity
Endotoxin Level
N-terminal Sequence Analysis
Predicted Molecular Mass
SDS-PAGE
Activity
When Recombinant Mouse CD40/TNFRSF5 Fc Chimera is immobilized at 1 µg/mL (100 µL/well), the concentration of Recombinant Mouse CD40 Ligand/TNFSF5 (Catalog # 8230-CL) that produces 50% optimal binding is found to be 100-600 ng/mL.
Formulation, Preparation and Storage
1215-CD
Formulation | Lyophilized from a 0.2 μm filtered solution in PBS. |
Reconstitution |
Reconstitute at 100 μg/mL in sterile PBS.
|
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Background: CD40/TNFRSF5
CD40, also known as TNFRSF5, is a 32 kDa type I transmembrane glycoprotein member of the TNF receptor superfamily. Mature mouse CD40 consists of a 174 amino acid (aa) extracellular domain, a transmembrane domain, and a 74 aa cytoplasmic domain (1, 2). The extracellular domain of mouse CD40 shares 58% and 81% aa sequence identity with human and rat CD40, respectively. Multiple mouse CD40 splice variants have been identified including soluble isoforms. CD40 is expressed on the surface of B cells, dendritic cells, macrophages, monocytes and platelets, as well as endothelial and epithelial cells (3, 4). Interaction of CD40 with its ligand, CD40 Ligand, leads to the aggregation of CD40 molecules resulting in the initiation of intracellular signaling in both CD40 and CD40 Ligand expressing cells (5). CD40 ligation by CD40 Ligand promotes B cell activation and T cell-dependent humoral responses (6, 7). CD40 serves multiple functions in both hematopoietic and epithelial cancers and is a target for tumor immunotherapy (8, 9). Dysregulation of CD40/CD40 Ligand expression and interactions contributes to the immune deficiency associated with HIV infection and AIDS (10, 11). It is also implicated in the pathology of multiple cardiovascular diseases including atherosclerosis, atherothrombosis, and restenosis (12, 13).
References
- Torres, R.M. and E.A. Clark (1992) J. Immunol. 148:620.
- Torres, R.M. et al. (1992) J. Immunol. 149:2641.
- van Kooten, C. and J. Banchereau (1997) Curr. Opin. Immunol. 9:330.
- Schonbeck, U. et al. (1997) J. Biol. Chem. 272:19569.
- Eissner, G. et al. (2004) Cytokine Growth Factor Rev. 15:353.
- Rickert, R.C. et al. (2011) Immunol. Rev. 244:115.
- Elgueta, R. et al. (2009) Immunol. Rev. 229:152.
- Loskog, A.S. and A.G. Eliopoulos (2009) Semin. Immunol. 21:301.
- Hangalapura, B.N. et al. (2012) J. Gene Med. 14:416.
- Kornbluth, R.S. (2000) J. Leukoc. Biol. 68:373.
- Chougnet, C. (2003) J. Leukoc. Biol. 74:702.
- Pamukcu, B. et al. (2011) Ann. Med. 43:331.
- Hassan, G.S. et al. (2012) Immunobiology 217:521.
Alternate Names
Gene Symbol
UniProt
Additional CD40/TNFRSF5 Products
Product Documents for Recombinant Mouse CD40/TNFRSF5 Fc Chimera Protein, CF
Product Specific Notices for Recombinant Mouse CD40/TNFRSF5 Fc Chimera Protein, CF
For research use only